The group's principal activity is to identify, develop and commercialize novel drugs for cancer and related diseases. The research program of the group is focused mainly on dna/rna medicines and small molecules. Dna/rna medicines are based on chemical modifications of either deoxyribonucleic acid or dna or ribonucleic acid or rna. Ganitetm, which forms part of small molecules program, is the first commercial product of the group. Ganitetm has been approved by the U.S. Food and drug administration for treatment of cancer-related hypercalcemia that is resistant to hydration. The group derives its revenues from three segments: product sales, license fees and royalties and development funding.
Executive Information
Name
Title
Email
Raymond Warrell
Chmn., CEO
N/A
Loretta Itri
Pres. - Pharmaceutical Development, Chief Medical Officer
